Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

(marketscreener.com) Company Will Explore Use of NeXT Personal® in AstraZeneca Trialhttps://www.marketscreener.com/quote/stock/PERSONALIS-INC-60037648/news/Personalis-Selected-for-Clinical-Research-After-Successful-Evaluation-of-Whole-Genome-Based-Molecula-43181154/?utm_medium=RSS&utm_content=20230307